Details of the Drug

General Information of Drug (ID: DM2TEOL)

Drug Name
Methotrexate
Synonyms
methotrexate; 1959/5/2; Rheumatrex; Amethopterin; Metatrexan; Hdmtx; Abitrexate; Mexate; Methylaminopterinum; Methotrexatum; Antifolan; Metotrexato; Methylaminopterin; MTX; (S)-2-(4-(((2,4-Diaminopteridin-6-yl)methyl)(methyl)amino)benzamido)pentanedioic acid; Methotrexat; Amethopterine; Maxtrex; Rasuvo; L-Amethopterin; A-Methopterin; A-Methpterin; Amethopterin L-; Folex-Pfs; Methotrexat-Ebewe; N-Bismethylpteroylglutamic acid; Methotrexate, L-; Metotressato [DCIT]; Methotextrate; Mexate-Aq; [3H]methotrexate
Indication
Disease Entry ICD 11 Status REF
Anterior urethra cancer N.A. Approved [1]
Burkitt lymphoma N.A. Approved [1]
Childhood acute lymphoblastic leukemia N.A. Approved [1]
Choriocarcinoma 2C75.0 Approved [2]
Gestational trophoblastic neoplasia 2F33-2F76 Approved [1]
Head and neck cancer 2D42 Approved [1]
Inflammation 1A00-CA43.1 Approved [1]
leukaemia 2A60-2B33 Approved [3]
Leukemia N.A. Approved [1]
Lung cancer 2C25.0 Approved [1]
Mycosis fungoides 2B01 Approved [1]
Posterior urethra cancer N.A. Approved [1]
Psoriasis EA90 Approved [1]
Sensorineural hearing loss disorder N.A. Approved [1]
Urticaria EB00-EB05 Approved [1]
Proliferative vitreoretinopathy 9B78.2 Phase 3 [4]
Solid tumour/cancer 2A00-2F9Z Phase 3 [3]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 1/2 [5]
Rheumatoid arthritis FA20 Phase 1 [6]
Prostate cancer 2C82.0 Investigative [7]
⏷ Show the Full List of Indication(s)
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 454.4
Logarithm of the Partition Coefficient (xlogp) -1.8
Rotatable Bond Count (rotbonds) 9
Hydrogen Bond Donor Count (hbonddonor) 5
Hydrogen Bond Acceptor Count (hbondacc) 12
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Apoptosis Not Available TK1 OTY5JFM1 [8]
Chromosomal abnormalities and abnormal gene carriers Not Available UNG OTZTWD86 [8]
Death Not Available GOT1 OTZLM5UB [8]
Dose-limiting toxicity rs1801133 MTHFR OTUBJSR7 [9]
Liver injury Not Available LAMP1 OTYE92QY [8]
Traumatic lung injury Not Available SFTPD OTNKPDJC [8]
⏷ Show the Full List of 6 ADR Information of This Drug
Chemical Identifiers
Formula
C20H22N8O5
IUPAC Name
(2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid
Canonical SMILES
CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O
InChI
InChI=1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1
InChIKey
FBOZXECLQNJBKD-ZDUSSCGKSA-N
Cross-matching ID
PubChem CID
126941
ChEBI ID
CHEBI:44185
CAS Number
59-05-2
DrugBank ID
DB00563
TTD ID
D0SV8E
VARIDT ID
DR00082
INTEDE ID
DR1045
ACDINA ID
D00412
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Proton-coupled folate transporter (SLC46A1) TTY8Z2E PCFT_HUMAN Modulator [10]
Solute carrier family 19 member 1 (SLC19A1) TT09I7D S19A1_HUMAN Modulator [11]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug resistance-associated protein 8 (ABCC11) DTWN7FC ABCCB_HUMAN Substrate [12]
Folate transporter 1 (SLC19A1) DTOSN46 S19A1_HUMAN Substrate [13]
Proton-coupled folate transporter (SLC46A1) DTDJEMI PCFT_HUMAN Substrate [14]
Multidrug resistance-associated protein 5 (ABCC5) DTYVM24 MRP5_HUMAN Substrate [15]
Organic anion transporter 2 (SLC22A7) DT0OC1Q S22A7_HUMAN Substrate [16]
Multidrug resistance-associated protein 3 (ABCC3) DTQ3ZHF MRP3_HUMAN Substrate [17]
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [18]
Organic anion transporter 4 (SLC22A11) DT06JWZ S22AB_HUMAN Substrate [19]
Multidrug resistance-associated protein 4 (ABCC4) DTCSGPB MRP4_HUMAN Substrate [20]
Organic anion transporting polypeptide 1A2 (SLCO1A2) DTE2B1D SO1A2_HUMAN Substrate [21]
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [22]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [23]
Organic anion transporter 1 (SLC22A6) DTQ23VB S22A6_HUMAN Substrate [24]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [25]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [26]
Organic anion transporter 3 (SLC22A8) DTVP67E S22A8_HUMAN Substrate [27]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [28]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Thymidylate synthase (TYMS) DEASG0Q TYSY_HUMAN Substrate [29]
Dihydrofolate reductase (DHFR) DE4EGMZ DYR_HUMAN Substrate [29]
Methylenetetrahydrofolate reductase (MTHFR) DEOXTPZ MTHR_HUMAN Substrate [29]
Folylpolyglutamate synthase (FPGS) DECWT2V FOLC_HUMAN Substrate [29]
Gamma-Glu-X carboxypeptidase (GGH) DEU7MWJ GGH_HUMAN Substrate [29]
Thiopurine methyltransferase (TPMT) DEFQ8VO TPMT_HUMAN Substrate [30]
Glutamate carboxypeptidase II (FOLH1) DEN8V7Z FOLH1_HUMAN Substrate [31]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
1-acyl-sn-glycerol-3-phosphate acyltransferase gamma (AGPAT3) OTAUR5TG PLCC_HUMAN Gene/Protein Processing [32]
1-acylglycerol-3-phosphate O-acyltransferase PNPLA3 (PNPLA3) OTR4990X PLPL3_HUMAN Gene/Protein Processing [32]
11-beta-hydroxysteroid dehydrogenase 1 (HSD11B1) OTO7FJA9 DHI1_HUMAN Gene/Protein Processing [33]
14-3-3 protein sigma (SFN) OTLJCZ1U 1433S_HUMAN Gene/Protein Processing [34]
15-hydroxyprostaglandin dehydrogenase (HPGD) OTYZI6JB PGDH_HUMAN Gene/Protein Processing [32]
2'-5'-oligoadenylate synthase 1 (OAS1) OT8ZLOCY OAS1_HUMAN Gene/Protein Processing [33]
2-oxoglutarate dehydrogenase complex component E1 (OGDH) OTHGTQWF ODO1_HUMAN Gene/Protein Processing [35]
2-oxoglutarate receptor 1 (OXGR1) OT2D4V93 OXGR1_HUMAN Gene/Protein Processing [36]
26S proteasome non-ATPase regulatory subunit 9 (PSMD9) OT6Y5CC3 PSMD9_HUMAN Gene/Protein Processing [36]
3',5'-cyclic-AMP phosphodiesterase 4C (PDE4C) OTI8VMHZ PDE4C_HUMAN Gene/Protein Processing [36]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Methotrexate (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [37]
Sodium bicarbonate DMMU6BJ Minor as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Methotrexate caused by Sodium bicarbonate mediated altered urine pH. Acidosis [5C73] [38]
Tromethamine DMOBLGK Minor as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Methotrexate caused by Tromethamine mediated altered urine pH. Acidosis [5C73] [38]
Tretinoin DM49DUI Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Tretinoin. Acne vulgaris [ED80] [39]
Isotretinoin DM4QTBN Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Isotretinoin. Acne vulgaris [ED80] [39]
Nicotinamide DMUPE07 Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Nicotinamide. Acquired cutaneous blood vessel malformation [EF20] [39]
Pioglitazone DMKJ485 Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Pioglitazone. Acute diabete complication [5A2Y] [39]
Midostaurin DMI6E0R Moderate Decreased clearance of Methotrexate due to the transporter inhibition by Midostaurin. Acute myeloid leukaemia [2A60] [39]
Arn-509 DMT81LZ Moderate Accelerated clearance of Methotrexate due to the transporter induction by Arn-509. Acute myeloid leukaemia [2A60] [39]
Gilteritinib DMTI0ZO Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Gilteritinib. Acute myeloid leukaemia [2A60] [39]
Framycetin DMF8DNE Moderate Altered absorption of Methotrexate caused by Framycetin. Alcoholic liver disease [DB94] [40]
Oxandrolone DMU9MYJ Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Oxandrolone. Alcoholic liver disease [DB94] [39]
Paromomycin DM1AGXN Moderate Altered absorption of Methotrexate caused by Paromomycin. Amoebiasis [1A36] [40]
Inotersen DMJ93CT Major Increased risk of nephrotoxicity by the combination of Methotrexate and Inotersen. Amyloidosis [5D00] [39]
Dronedarone DMA8FS5 Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Dronedarone. Angina pectoris [BA40] [39]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [41]
Oxymetholone DMFXUT8 Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Oxymetholone. Aplastic anaemia [3A70] [39]
Voriconazole DMAOL2S Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Voriconazole. Aspergillosis [1F20] [39]
Posaconazole DMUL5EW Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Posaconazole. Aspergillosis [1F20] [39]
Budesonide DMJIBAW Moderate Additive immunosuppressive effects by the combination of Methotrexate and Budesonide. Asthma [CA23] [42]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Methotrexate and Roflumilast. Asthma [CA23] [39]
Zileuton DMVRIC2 Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Zileuton. Asthma [CA23] [39]
Kanamycin DM2DMPO Moderate Altered absorption of Methotrexate caused by Kanamycin. Bacterial infection [1A00-1C4Z] [40]
Clavulanate DM2FGRT Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Clavulanate. Bacterial infection [1A00-1C4Z] [39]
Clarithromycin DM4M1SG Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Clarithromycin. Bacterial infection [1A00-1C4Z] [39]
Ticarcillin DM4ME02 Major Decreased elimination of Methotrexate caused by Ticarcillin mediated competitive inhibition of renal tubular secretion. Bacterial infection [1A00-1C4Z] [43]
Sulfamethoxazole DMB08GE Moderate Increased plasma concentration of Methotrexate and Sulfamethoxazole due to competitive binding of plasma proteins. Bacterial infection [1A00-1C4Z] [44]
Meticillin DMIKHN0 Major Decreased elimination of Methotrexate caused by Meticillin mediated competitive inhibition of renal tubular secretion. Bacterial infection [1A00-1C4Z] [45]
Oxytetracycline DMOVH1M Moderate Increased plasma concentration of Methotrexate and Oxytetracycline due to competitive binding of plasma proteins. Bacterial infection [1A00-1C4Z] [46]
Bacampicillin DMP54C7 Major Decreased elimination of Methotrexate caused by Bacampicillin mediated competitive inhibition of renal tubular secretion. Bacterial infection [1A00-1C4Z] [43]
Oxacillin DMTAFY4 Major Decreased elimination of Methotrexate caused by Oxacillin mediated competitive inhibition of renal tubular secretion. Bacterial infection [1A00-1C4Z] [43]
Cloxacillin DMUTL7O Major Decreased elimination of Methotrexate caused by Cloxacillin mediated competitive inhibition of renal tubular secretion. Bacterial infection [1A00-1C4Z] [43]
Amoxicillin DMUYNEI Major Decreased elimination of Methotrexate caused by Amoxicillin mediated competitive inhibition of renal tubular secretion. Bacterial infection [1A00-1C4Z] [43]
Minocycline DMVN5OH Moderate Increased plasma concentration of Methotrexate and Minocycline due to competitive binding of plasma proteins. Bacterial infection [1A00-1C4Z] [46]
Telithromycin DMZ4P3A Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Telithromycin. Bacterial infection [1A00-1C4Z] [39]
Tetracycline DMZA017 Moderate Increased plasma concentration of Methotrexate and Tetracycline due to competitive binding of plasma proteins. Bacterial infection [1A00-1C4Z] [46]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Methotrexate and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [47]
Lomustine DMMWSUL Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Lomustine. Brain cancer [2A00] [39]
Lapatinib DM3BH1Y Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Lapatinib. Breast cancer [2C60-2C6Y] [39]
LY2835219 DM93VBZ Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and LY2835219. Breast cancer [2C60-2C6Y] [39]
Pralatrexate DMAO80I Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Pralatrexate. Breast cancer [2C60-2C6Y] [39]
Tucatinib DMBESUA Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Tucatinib. Breast cancer [2C60-2C6Y] [39]
Tamoxifen DMLB0EZ Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Tamoxifen. Breast cancer [2C60-2C6Y] [39]
Bosutinib DMTI8YE Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Bosutinib. Breast cancer [2C60-2C6Y] [39]
Trastuzumab Emtansine DMU1LXS Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Trastuzumab Emtansine. Breast cancer [2C60-2C6Y] [39]
Fluoxymesterone DMUHCF1 Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Fluoxymesterone. Breast cancer [2C60-2C6Y] [39]
Demeclocycline DMZEPFJ Moderate Increased plasma concentration of Methotrexate and Demeclocycline due to competitive binding of plasma proteins. Bronchitis [CA20] [46]
Atorvastatin DMF28YC Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Atorvastatin. Cardiovascular disease [BA00-BE2Z] [39]
Fenofibric acid DMGO2MC Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Fenofibric acid. Cardiovascular disease [BA00-BE2Z] [39]
Macitentan DMP79A1 Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Macitentan. Cardiovascular disease [BA00-BE2Z] [39]
Chenodiol DMQ8JIK Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Chenodiol. Cholelithiasis [DC11] [39]
Iodipamide DMXIQYS Major Increased risk of nephrotoxicity by the combination of Methotrexate and Iodipamide. Cholelithiasis [DC11] [48]
Corticotropin DMP9TWZ Moderate Additive immunosuppressive effects by the combination of Methotrexate and Corticotropin. Chronic kidney disease [GB61] [42]
Phenylbutazone DMAYL0T Major Increased risk of nephrotoxicity by the combination of Methotrexate and Phenylbutazone. Chronic pain [MG30] [49]
Ketoprofen DMRKXPT Major Increased risk of nephrotoxicity by the combination of Methotrexate and Ketoprofen. Chronic pain [MG30] [49]
Regorafenib DMHSY1I Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Regorafenib. Colorectal cancer [2B91] [37]
Intedanib DMSTA36 Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Intedanib. Colorectal cancer [2B91] [39]
Methoxyflurane DML0RAE Moderate Increased risk of nephrotoxicity by the combination of Methotrexate and Methoxyflurane. Corneal disease [9A76-9A78] [39]
Pasireotide DMHM7JS Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Pasireotide. Cushing syndrome [5A70] [39]
Ivacaftor DMZC1HS Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Ivacaftor. Cystic fibrosis [CA25] [39]
Ethanol DMDRQZU Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Ethanol. Cystitis [GC00] [39]
Nefazodone DM4ZS8M Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Nefazodone. Depression [6A70-6A7Z] [39]
Milnacipran DMBFE74 Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Milnacipran. Depression [6A70-6A7Z] [39]
Polatuzumab vedotin DMF6Y0L Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Polatuzumab vedotin. Diffuse large B-cell lymphoma [2A81] [39]
PMID28454500-Compound-96 DM2A75P Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and PMID28454500-Compound-96. Discovery agent [N.A.] [39]
SODIUM CITRATE DMHPD2Y Minor as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Methotrexate caused by SODIUM CITRATE mediated altered urine pH. Discovery agent [N.A.] [38]
Benzylpenicillin DMS9503 Major Decreased elimination of Methotrexate caused by Benzylpenicillin mediated competitive inhibition of renal tubular secretion. Discovery agent [N.A.] [45]
Felbamate DM1V5ZS Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Felbamate. Epilepsy/seizure [8A61-8A6Z] [39]
Fosphenytoin DMOX3LB Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Fosphenytoin. Epilepsy/seizure [8A61-8A6Z] [39]
Ethotoin DMXWOCP Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Ethotoin. Epilepsy/seizure [8A61-8A6Z] [39]
Carbamazepine DMZOLBI Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Carbamazepine. Epilepsy/seizure [8A61-8A6Z] [39]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Cannabidiol. Epileptic encephalopathy [8A62] [39]
Mefenamic acid DMK7HFI Major Increased risk of nephrotoxicity by the combination of Methotrexate and Mefenamic acid. Female pelvic pain [GA34] [49]
Dantrolene DM1D8XY Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Dantrolene. Fever [MG26] [39]
Itraconazole DMCR1MV Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Itraconazole. Fungal infection [1F29-1F2F] [39]
Terbinafine DMI6HUW Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Terbinafine. Fungal infection [1F29-1F2F] [39]
Ketoconazole DMPZI3Q Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Ketoconazole. Fungal infection [1F29-1F2F] [39]
Amphotericin B DMTAJQE Moderate Increased risk of nephrotoxicity by the combination of Methotrexate and Amphotericin B. Fungal infection [1F29-1F2F] [37]
Atovaquone DMY4UMW Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Atovaquone. Fungal infection [1F29-1F2F] [39]
Sunitinib DMCBJSR Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Sunitinib. Gastrointestinal stromal tumour [2B5B] [39]
Lamivudine DMI347A Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Lamivudine. Hepatitis virus infection [1E50-1E51] [39]
177Lu-DOTATATE DMT8GVU Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and 177Lu-DOTATATE. Hepatitis virus infection [1E50-1E51] [39]
Rifampin DMA8J1G Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Rifampin. HIV-infected patients with tuberculosis [1B10-1B14] [39]
Fostemsavir DM50ILT Moderate Decreased clearance of Methotrexate due to the transporter inhibition by Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [50]
Stavudine DM6DEK9 Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Stavudine. Human immunodeficiency virus disease [1C60-1C62] [39]
Tipranavir DM8HJX6 Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Tipranavir. Human immunodeficiency virus disease [1C60-1C62] [39]
Emtricitabine DMBMUWZ Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Emtricitabine. Human immunodeficiency virus disease [1C60-1C62] [39]
Efavirenz DMC0GSJ Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [39]
Zalcitabine DMH7MUV Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Zalcitabine. Human immunodeficiency virus disease [1C60-1C62] [39]
Rilpivirine DMJ0QOW Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [39]
Abacavir DMMN36E Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Abacavir. Human immunodeficiency virus disease [1C60-1C62] [39]
Darunavir DMN3GCH Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Darunavir. Human immunodeficiency virus disease [1C60-1C62] [39]
Maraviroc DMTL94F Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Maraviroc. Human immunodeficiency virus disease [1C60-1C62] [39]
Bempedoic acid DM1CI9R Moderate Decreased clearance of Methotrexate due to the transporter inhibition by Bempedoic acid. Hyper-lipoproteinaemia [5C80] [51]
Simvastatin DM30SGU Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Simvastatin. Hyper-lipoproteinaemia [5C80] [39]
Fluvastatin DM4MDJY Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Fluvastatin. Hyper-lipoproteinaemia [5C80] [39]
Fenofibrate DMFKXDY Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Fenofibrate. Hyper-lipoproteinaemia [5C80] [39]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Methotrexate and Mipomersen. Hyper-lipoproteinaemia [5C80] [52]
Rosuvastatin DMMIQ7G Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Rosuvastatin. Hyper-lipoproteinaemia [5C80] [39]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Methotrexate and Teriflunomide. Hyper-lipoproteinaemia [5C80] [53]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Methotrexate and BMS-201038. Hyper-lipoproteinaemia [5C80] [54]
Moexipril DM26E4B Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Moexipril. Hypertension [BA00-BA04] [39]
Captopril DM458UM Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Captopril. Hypertension [BA00-BA04] [39]
Methyldopa DM5I621 Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Methyldopa. Hypertension [BA00-BA04] [39]
Labetalol DMK8U72 Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Labetalol. Hypertension [BA00-BA04] [39]
Enalapril DMNFUZR Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Enalapril. Hypertension [BA00-BA04] [39]
Perindopril DMOPZDT Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Perindopril. Hypertension [BA00-BA04] [39]
Quinapril DMR8H31 Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Quinapril. Hypertension [BA00-BA04] [39]
Sodium acetate anhydrous DMH21E0 Minor as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Methotrexate caused by Sodium acetate anhydrous mediated altered urine pH. Hypo-osmolality/hyponatraemia [5C72] [38]
Tolvaptan DMIWFRL Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [39]
Fludrocortisone DMUDIR8 Moderate Additive immunosuppressive effects by the combination of Methotrexate and Fludrocortisone. Hypo-osmolality/hyponatraemia [5C72] [42]
Pirfenidone DM6VZFQ Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Pirfenidone. Idiopathic interstitial pneumonitis [CB03] [39]
Vitamin B3 DMQVRZH Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Vitamin B3. Inborn lipid metabolism error [5C52] [39]
Givosiran DM5PFIJ Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Givosiran. Inborn porphyrin/heme metabolism error [5C58] [39]
Febuxostat DMDEXQ0 Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Febuxostat. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [39]
Balsalazide DM7I1T9 Moderate Increased risk of nephrotoxicity by the combination of Methotrexate and Balsalazide. Indeterminate colitis [DD72] [55]
Meclofenamic acid DM05FXR Major Increased risk of nephrotoxicity by the combination of Methotrexate and Meclofenamic acid. Inflammatory spondyloarthritis [FA92] [56]
Testosterone DM7HUNW Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Testosterone. Low bone mass disorder [FB83] [39]
Denosumab DMNI0KO Moderate Additive immunosuppressive effects by the combination of Methotrexate and Denosumab. Low bone mass disorder [FB83] [57]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Methotrexate and Porfimer Sodium. Lung cancer [2C25] [58]
Ceritinib DMB920Z Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Ceritinib. Lung cancer [2C25] [39]
Lurbinectedin DMEFRTZ Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Lurbinectedin. Lung cancer [2C25] [39]
BIBW 2992 DMTKD7Q Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and BIBW 2992. Lung cancer [2C25] [39]
Pralsetinib DMWU0I2 Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Pralsetinib. Lung cancer [2C25] [39]
Capmatinib DMYCXKL Moderate Decreased clearance of Methotrexate due to the transporter inhibition by Capmatinib. Lung cancer [2C25] [59]
Selpercatinib DMZR15V Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Selpercatinib. Lung cancer [2C25] [39]
Sulphadoxine DMZI2UF Moderate Increased plasma concentration of Methotrexate and Sulphadoxine due to competitive binding of plasma proteins. Malaria [1F40-1F45] [44]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [39]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [60]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Idelalisib. Mature B-cell leukaemia [2A82] [61]
IPI-145 DMWA24P Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and IPI-145. Mature B-cell leukaemia [2A82] [39]
Clofarabine DMCVJ86 Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Clofarabine. Mature B-cell lymphoma [2A85] [62]
Blinatumomab DMGECIJ Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Blinatumomab. Mature B-cell lymphoma [2A85] [39]
Mercaptopurine DMTM2IK Minor Decreased metabolism of Methotrexate caused by Mercaptopurine. Mature B-cell lymphoma [2A85] [63]
Ponatinib DMYGJQO Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Ponatinib. Mature B-cell lymphoma [2A85] [39]
Cytarabine DMZD5QR Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Cytarabine. Mature B-cell lymphoma [2A85] [37]
Arry-162 DM1P6FR Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Arry-162. Melanoma [2C30] [39]
Vemurafenib DM62UG5 Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Vemurafenib. Melanoma [2C30] [39]
Ipilimumab DMJTIYK Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Ipilimumab. Melanoma [2C30] [39]
Dacarbazine DMNPZL4 Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Dacarbazine. Melanoma [2C30] [39]
Danazol DML8KTN Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Danazol. Menstrual cycle bleeding disorder [GA20] [39]
Lasmiditan DMXLVDT Moderate Decreased clearance of Methotrexate due to the transporter inhibition by Lasmiditan. Migraine [8A80] [64]
Exjade DMHPRWG Major Increased risk of nephrotoxicity by the combination of Methotrexate and Exjade. Mineral absorption/transport disorder [5C64] [65]
Riluzole DMECBWN Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Riluzole. Motor neuron disease [8B60] [39]
Carfilzomib DM48K0X Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Carfilzomib. Multiple myeloma [2A83] [39]
Panobinostat DM58WKG Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Panobinostat. Multiple myeloma [2A83] [39]
Thalidomide DM70BU5 Major Additive thrombogenic effects by the combination of Methotrexate and Thalidomide. Multiple myeloma [2A83] [66]
Tecfidera DM2OVDT Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Tecfidera. Multiple sclerosis [8A40] [39]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Methotrexate and Siponimod. Multiple sclerosis [8A40] [37]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Methotrexate and Fingolimod. Multiple sclerosis [8A40] [67]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Methotrexate and Ocrelizumab. Multiple sclerosis [8A40] [68]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Methotrexate and Ozanimod. Multiple sclerosis [8A40] [39]
Nilotinib DM7HXWT Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Nilotinib. Myeloproliferative neoplasm [2A20] [39]
Imatinib DM7RJXL Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Imatinib. Myeloproliferative neoplasm [2A20] [39]
Rolapitant DM8XP26 Moderate Decreased clearance of Methotrexate due to the transporter inhibition by Rolapitant. Nausea/vomiting [MD90] [69]
Bupropion DM5PCS7 Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Bupropion. Nicotine use disorder [6C4A] [39]
Entrectinib DMMPTLH Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Entrectinib. Non-small cell lung cancer [2C25] [39]
Orlistat DMRJSP8 Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Orlistat. Obesity [5B80-5B81] [39]
Valdecoxib DMAY7H4 Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Valdecoxib. Osteoarthritis [FA00-FA05] [39]
Diclofenac DMPIHLS Major Increased risk of nephrotoxicity by the combination of Methotrexate and Diclofenac. Osteoarthritis [FA00-FA05] [49]
Naproxen DMZ5RGV Major Increased risk of nephrotoxicity by the combination of Methotrexate and Naproxen. Osteoarthritis [FA00-FA05] [49]
Rucaparib DM9PVX8 Moderate Decreased clearance of Methotrexate due to the transporter inhibition by Rucaparib. Ovarian cancer [2C73] [70]
Etodolac DM6WJO9 Major Increased risk of nephrotoxicity by the combination of Methotrexate and Etodolac. Pain [MG30-MG3Z] [49]
Ibuprofen DM8VCBE Major Increased risk of nephrotoxicity by the combination of Methotrexate and Ibuprofen. Pain [MG30-MG3Z] [49]
Pemetrexed DMMX2E6 Moderate Decreased renal excretion of Methotrexate caused by Pemetrexed mediated nephrotoxicity. Pleural mesothelioma [2C26] [71]
Prednisone DM2HG4X Moderate Additive immunosuppressive effects by the combination of Methotrexate and Prednisone. Postoperative inflammation [1A00-CA43] [42]
Hydrocortisone DMGEMB7 Moderate Additive immunosuppressive effects by the combination of Methotrexate and Hydrocortisone. Postoperative inflammation [1A00-CA43] [42]
Bromfenac DMKB79O Major Increased risk of nephrotoxicity by the combination of Methotrexate and Bromfenac. Postoperative inflammation [1A00-CA43] [49]
ABIRATERONE DM8V75C Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and ABIRATERONE. Prostate cancer [2C82] [39]
Nilutamide DMFN07X Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Nilutamide. Prostate cancer [2C82] [39]
Darolutamide DMV7YFT Moderate Decreased clearance of Methotrexate due to the transporter inhibition by Darolutamide. Prostate cancer [2C82] [72]
Bicalutamide DMZMSPF Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Bicalutamide. Prostate cancer [2C82] [39]
Ambrisentan DMD1QXW Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Ambrisentan. Pulmonary hypertension [BB01] [39]
Axitinib DMGVH6N Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Axitinib. Renal cell carcinoma [2C90] [39]
Temsirolimus DMS104F Major Increased risk of nephrotoxicity by the combination of Methotrexate and Temsirolimus. Renal cell carcinoma [2C90] [73]
Meloxicam DM2AR7L Major Increased risk of nephrotoxicity by the combination of Methotrexate and Meloxicam. Rheumatoid arthritis [FA20] [49]
Sulindac DM2QHZU Major Increased risk of nephrotoxicity by the combination of Methotrexate and Sulindac. Rheumatoid arthritis [FA20] [49]
Tocilizumab DM7J6OR Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Tocilizumab. Rheumatoid arthritis [FA20] [39]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Methotrexate and Canakinumab. Rheumatoid arthritis [FA20] [74]
Oxaprozin DM9UB0P Major Increased risk of nephrotoxicity by the combination of Methotrexate and Oxaprozin. Rheumatoid arthritis [FA20] [49]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Methotrexate and Rilonacept. Rheumatoid arthritis [FA20] [74]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Methotrexate and Golimumab. Rheumatoid arthritis [FA20] [75]
Sulfasalazine DMICA9H Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Sulfasalazine. Rheumatoid arthritis [FA20] [39]
Fenoprofen DML5VQ0 Major Increased risk of nephrotoxicity by the combination of Methotrexate and Fenoprofen. Rheumatoid arthritis [FA20] [49]
Dexamethasone DMMWZET Moderate Additive immunosuppressive effects by the combination of Methotrexate and Dexamethasone. Rheumatoid arthritis [FA20] [42]
Sarilumab DMOGNXY Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Sarilumab. Rheumatoid arthritis [FA20] [39]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Methotrexate and Leflunomide. Rheumatoid arthritis [FA20] [53]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Methotrexate when combined with Anthrax vaccine. Sepsis [1G40-1G41] [76]
Tedizolid DMG2SKR Moderate Decreased clearance of Methotrexate due to the transporter inhibition by Tedizolid. Skin and skin-structure infection [1F28-1G0Z] [39]
Larotrectinib DM26CQR Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Larotrectinib. Solid tumour/cancer [2A00-2F9Z] [39]
Methylprednisolone DM4BDON Moderate Additive immunosuppressive effects by the combination of Methotrexate and Methylprednisolone. Solid tumour/cancer [2A00-2F9Z] [42]
PDX-101 DM6OC53 Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and PDX-101. Solid tumour/cancer [2A00-2F9Z] [39]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [39]
Prednisolone DMQ8FR2 Moderate Additive immunosuppressive effects by the combination of Methotrexate and Prednisolone. Solid tumour/cancer [2A00-2F9Z] [42]
Methyltestosterone DMWLFGO Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Methyltestosterone. Solid tumour/cancer [2A00-2F9Z] [39]
Disulfiram DMCL2OK Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Disulfiram. Substance abuse [6C40] [39]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Naltrexone. Substance abuse [6C40] [39]
Fostamatinib DM6AUHV Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Fostamatinib. Thrombocytopenia [3B64] [39]
Eltrombopag DMOGFIX Moderate Decreased clearance of Methotrexate due to the transporter inhibition by Eltrombopag. Thrombocytopenia [3B64] [77]
Lenvatinib DMB1IU4 Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Lenvatinib. Thyroid cancer [2D10] [39]
Methimazole DM25FL8 Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Methimazole. Thyrotoxicosis [5A02] [39]
Tizanidine DMR2IQ4 Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Tizanidine. Tonus and reflex abnormality [MB47] [39]
Trimetrexate DMDEA85 Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Trimetrexate. Toxoplasmosis [1F57] [39]
Sirolimus DMGW1ID Major Increased risk of nephrotoxicity by the combination of Methotrexate and Sirolimus. Transplant rejection [NE84] [73]
Azathioprine DMMZSXQ Minor Decreased metabolism of Methotrexate caused by Azathioprine. Transplant rejection [NE84] [63]
Tacrolimus DMZ7XNQ Major Increased risk of nephrotoxicity by the combination of Methotrexate and Tacrolimus. Transplant rejection [NE84] [73]
Olsalazine DMZW9HA Moderate Increased risk of nephrotoxicity by the combination of Methotrexate and Olsalazine. Ulcerative colitis [DD71] [55]
Nitrofurantoin DM7PQIK Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Nitrofurantoin. Urinary tract infection [GC08] [39]
Sulfamethizole DMGCHDS Moderate Increased plasma concentration of Methotrexate and Sulfamethizole due to competitive binding of plasma proteins. Urinary tract infection [GC08] [44]
Plazomicin DMKMBES Moderate Increased risk of nephrotoxicity by the combination of Methotrexate and Plazomicin. Urinary tract infection [GC08] [37]
Carbenicillin DMLEDNK Major Decreased elimination of Methotrexate caused by Carbenicillin mediated competitive inhibition of renal tubular secretion. Urinary tract infection [GC08] [43]
Mezlocillin DMY5JEP Major Decreased elimination of Methotrexate caused by Mezlocillin mediated competitive inhibition of renal tubular secretion. Urinary tract infection [GC08] [43]
Elagolix DMB2C0E Moderate Increased risk of hepatotoxicity by the combination of Methotrexate and Elagolix. Uterine fibroid [2E86] [39]
Triamcinolone DM98IXF Moderate Additive immunosuppressive effects by the combination of Methotrexate and Triamcinolone. Vasomotor/allergic rhinitis [CA08] [42]
Ganciclovir DM1MBYQ Moderate Additive myelosuppressive effects by the combination of Methotrexate and Ganciclovir. Virus infection [1A24-1D9Z] [37]
Valaciclovir DMHKS94 Moderate Increased risk of nephrotoxicity by the combination of Methotrexate and Valaciclovir. Virus infection [1A24-1D9Z] [39]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Methotrexate and Valganciclovir. Virus infection [1A24-1D9Z] [37]
⏷ Show the Full List of 217 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF E00255 17730 Colorant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium carbonate monohydrate E00454 2735133 Alkalizing agent; Buffering agent; Diluent; Dispersing agent
Sodium hydroxide E00234 14798 Alkalizing agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
⏷ Show the Full List of 18 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Methotrexate 15 mg tablet 15 mg Oral Tablet Oral
Methotrexate 5 mg tablet 5 mg Oral Tablet Oral
Methotrexate 10 mg tablet 10 mg Oral Tablet Oral
Methotrexate 7.5 mg tablet 7.5 mg Oral Tablet Oral
Methotrexate 2.5 mg tablet 2.5 mg Oral Tablet Oral
Methotrexate Sodium 2.5mg tablet 2.5mg Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Methotrexate FDA Label
2 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 040632.
3 Pain reduction with oral methotrexate in knee osteoarthritis, a pragmatic phase iii trial of treatment effectiveness (PROMOTE): study protocol for ... Trials. 2015 Mar 4;16:77.
4 ClinicalTrials.gov (NCT04136366) The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy. U.S. National Institutes of Health.
5 ClinicalTrials.gov (NCT04352465) Efficacy and Safety of MTX-loaded Nanoparticles to Treat Severe COVID-19 Patients. U.S. National Institutes of Health.
6 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034238)
7 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
8 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
9 Methylenetetrahydrofolate reductase C677T and A1298C gene variants in adult non-Hodgkin's lymphoma patients: association with toxicity and survival. Haematologica. 2007 Apr;92(4):478-85. doi: 10.3324/haematol.10587.
10 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1213).
11 Increased activity of a novel low pH folate transporter associated with lipophilic antifolate resistance in chinese hamster ovary cells. J Biol Chem. 1998 Apr 3;273(14):8106-11.
12 ABCC11/MRP8 confers pemetrexed resistance in lung cancer. Cancer Sci. 2010 Nov;101(11):2404-10.
13 Biology of the major facilitative folate transporters SLC19A1 and SLC46A1. Curr Top Membr. 2014;73:175-204.
14 Site-specific contribution of proton-coupled folate transporter/haem carrier protein 1 in the intestinal absorption of methotrexate in rats. J Pharm Pharmacol. 2009 Jul;61(7):911-8.
15 The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. Cancer Res. 2005 May 15;65(10):4425-30.
16 Transport of organic anions across the basolateral membrane of proximal tubule cells. Rev Physiol Biochem Pharmacol. 2003;146:95-158.
17 Multidrug resistance protein (MRP) 1 and MRP3 attenuate cytotoxic and transactivating effects of the cyclopentenone prostaglandin, 15-deoxy-Delta(12,14)prostaglandin J2 in MCF7 breast cancer cells. Biochemistry. 2003 May 13;42(18):5429-37.
18 Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61.
19 Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71.
20 Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J Pharmacol Exp Ther. 2007 Jan;320(1):229-35.
21 Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther. 2006 Aug;318(2):521-9.
22 Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32.
23 Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
24 Transport of aminopterin by human organic anion transporters hOAT1 and hOAT3: Comparison with methotrexate. Drug Metab Pharmacokinet. 2010;25(2):163-9.
25 Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo. Mol Pharm. 2015 Dec 7;12(12):4259-69.
26 LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001 Jun;120(7):1689-99.
27 Methotrexate-loxoprofen interaction: involvement of human organic anion transporters hOAT1 and hOAT3. Drug Metab Pharmacokinet. 2004 Oct;19(5):369-74.
28 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
29 The pharmacogenetics of methotrexate. Rheumatology (Oxford). 2007 Oct;46(10):1520-4.
30 Genetics of rheumatoid arthritis. Mayo Clin Proc. 2006 Jan;81(1):94-101.
31 Understanding and managing methotrexate nephrotoxicity. Oncologist. 2006 Jun;11(6):694-703.
32 The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
33 Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
34 Gene expression profiling of rheumatoid arthritis synovial cells treated with antirheumatic drugs. J Biomol Screen. 2007 Apr;12(3):328-40. doi: 10.1177/1087057107299261. Epub 2007 Mar 22.
35 Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
36 Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
37 Cerner Multum, Inc. "Australian Product Information.".
38 Nirenberg A, Mosende C, Mehta BM, Gisolfi AL, Rosen G "High-dose methotrexate with citrovorum factor rescue: predictive value of serum methotrexate concentrations and corrective measures to avert toxicity." Cancer Treat Rep 61 (1977): 779-83. [PMID: 302143]
39 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
40 Keusch GT, Troncale FJ, Buchanan RD "Malabsorption due to paromomycin." Arch Intern Med 125 (1970): 273-6. [PMID: 5412015]
41 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
42 Lafforgue P, Monjanel-Mouterde S, Durand A, Catalin J, Acquaviva PC "Is there an interaction between low doses of corticosteroids and methotrexate in patients with rheumatoid arthritis? A pharmacokinetic study in 33 patients." J Rheumatol 20 (1993): 263-7. [PMID: 8474062]
43 Kwon OC, Lee JS, Kim YG, Lee CK, Yoo B, Hong S. Safety of the concomitant use of methotrexate and a prophylactic dose of trimethoprim-sulfamethoxazole.?Clin Rheumatol. 2018;37(12):3215-3220. [PMID: 29383453]
44 Bannwarth B, Pehourcq F, Schaeverbeke T, Dehais J "Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis." Clin Pharmacokinet 30 (1996): 194-210. [PMID: 8882301]
45 Dean R, Nachman J, Lorenzana AN "Possible methotrexate-mezlocillin interaction." Am J Pediatr Hematol Oncol 14 (1992): 88-92. [PMID: 1550270]
46 Canadian Pharmacists Association.
47 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
48 Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
49 Adams JD, Hunter GA "Drug interaction in psoriasis." Australas J Dermatol 17 (1976): 39-40. [PMID: 1022213]
50 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
51 Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
52 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
53 EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions.".
54 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
55 Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442. [PMID: 3132281]
56 Schwartz JI, Agrawal NG, Wong PH, et al. "Lack of pharmacokinetic interaction between rofecoxib and methotrexate in rheumatoid arthritis patients." J Clin Pharmacol 41 (2001): 1120-30. [PMID: 11583481]
57 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
58 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
59 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
60 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
61 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
62 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
63 Balis FM, Holcenberg JS, Zimm S, et al "The effect of methotrexate on the bioavailability of oral 6-mercaptopurine." Clin Pharmacol Ther 41 (1987): 384-7. [PMID: 3470165]
64 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
65 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
66 Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
67 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
68 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
69 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
70 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
71 Product Information. Alimta (pemetrexed). Lilly, Eli and Company, Indianapolis, IN.
72 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
73 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
74 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
75 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
76 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
77 Allred AJ, Bowen CJ, Park JW, et al. "Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers." Br J Clin Pharmacol 72 (2011): 321-9. [PMID: 21434975]